W. Rathmell
Last active: 11/27/2019

  1. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Cowey CL, Fielding JR, Rathmell WK (2010) Urology 75(5): 1108-13.e1
    › Primary publication · 19931124 (PubMed)
  2. Renal cell carcinoma: where will the state-of-the-art lead us? Brannon AR, Rathmell WK (2010) Curr Oncol Rep 12(3): 193-201
    › Primary publication · 20425079 (PubMed) · PMC2906141 (PubMed Central)
  3. Recent updates in renal cell carcinoma. Rathmell WK, Godley PA (2010) Curr Opin Oncol 22(3): 250-6
    › Primary publication · 20154618 (PubMed) · PMC2906148 (PubMed Central)
  4. Neoadjuvant treatment of renal cell carcinoma. Rathmell WK, Pruthi R, Wallen E (2010) Urol Oncol 28(1): 69-73
    › Primary publication · 20123351 (PubMed)
  5. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK (2010) J Clin Oncol 28(9): 1502-7
    › Primary publication · 20159822 (PubMed) · PMC4525128 (PubMed Central)
  6. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK (2010) Genes Cancer 1(2): 152-163
    › Primary publication · 20871783 (PubMed) · PMC2943630 (PubMed Central)
  7. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV (2010) BMC Syst Biol : 51
    › Primary publication · 20420713 (PubMed) · PMC2876063 (PubMed Central)
  8. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. Wright TM, Rathmell WK (2010) J Biol Chem 285(17): 12916-24
    › Primary publication · 20185829 (PubMed) · PMC2857057 (PubMed Central)
  9. Emerging molecular classification in renal cell carcinoma: implications for drug development. Hacker KE, Rathmell WK (2010) Target Oncol 5(2): 75-84
    › Primary publication · 20645016 (PubMed) · PMC3392717 (PubMed Central)
  10. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W (2010) BJU Int 106(3): 349-54
    › Primary publication · 20089114 (PubMed)